{'fraction_non_alphanumeric': 0.030534351145038167, 'fraction_numerical': 0.02099236641221374, 'mean_word_length': 5.402439024390244, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identification of Type I Interferon as a Novel Therapeutic Approach for Targeting Alveolar Rhabdomyosarcoma

Bone and soft tissue tumors (BSTT) are a group of neoplasms most commonly found in children. The TRE17/ ubiquitin‐specific protease 6 (USP6) oncogene is intimately involved in several BSTTs, including alveolar rhabdomyosarcoma (ARMS). The molecular functions of TRE17 in ARMS pathogenesis are unknown. However, recent unpublished data from our lab has identified the Jak1‐STAT1/3 pathway as a key effector of TRE17.